Share this page:
Title
Hydroxychloroquine prophylaxis for COVID-19 contacts in India
Subject
Description
More than a billion Indians currently stand at the precipice of a massive increase in cases of coronavirus disease 2019 (COVID-19). India had shown a staggered course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission, with 1397 cases diagnosed between Jan 31, and April 1, 2020. However, there has been a recent surge in cases, with numbers rising to 5194 as of April 8
Responses to this article was published:
Responses to this article was published:
- Tilangi, Praveen, Devashish Desai, Adil Khan, and Manish Soneja. 2020. "Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach." The Lancet Infectious Diseases.
- Afra, T. P., Muhammed Razmi T, Anuradha Bishnoi, and N. A. Bishurul Hafi. 2020. "Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?" The Lancet Infectious Diseases.
Date Last Updated (Year-Month-Day)
2020-04-17
Type
Citation
Rathi, Sahaj, Pranav Ish, Ashwini Kalantri, and Shriprakash Kalantri. 2020. "Hydroxychloroquine prophylaxis for COVID-19 contacts in India." The Lancet Infectious Diseases.
Accessibility
Free online on Lancet site.